Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Hackshaw MD, Bui CL, Ladner A, Tu N, Zahidu I, Ritchey ME, Salas M. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab post-trastuzumab gastric cancer. Cancer Treat Res Commun. 2020;24(2020). doi: 10.1016/j.ctarc.2020.100189
Domdey A, Njue A, Nuabor W, Lyall M, Heyes A, Elliott L. Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. Eur Ann Allergy Clin Immunol. 2019 Jul;51(4):147-58. doi: 10.23822/EurAnnACI.1764-1489.100
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.